DR info

Clinical trials : 41 / Drugs : 27 - (DrugBank : 8) / Drug target genes : 7 - Drug target pathways : 10

Drugs and their primary sponsors and trial info

C03XA01
   Department of Medical Research
      2014   Phase 2   EUCTR2013-003800-38-DK   Denmark;
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark;
Desmopressin Oral Melt
   Ferring Pharmaceuticals
      2011   Phase 3   NCT01280188   Japan;
Desmopressin intranasal
   Ferring Pharmaceuticals
      2011   Phase 3   NCT01280188   Japan;
Empagliflozin
   University Hospital, Basel, Switzerland
      2021   Phase 4   NCT04447911   Switzerland;
      2017   Phase 2/Phase 3   NCT03202667   Switzerland;
      2016   Phase 2/Phase 3   NCT02874807   Switzerland;
Empagliflozin 25mg Tbl
   University Hospital, Basel, Switzerland
      2016   Phase 2/Phase 3   NCT02729766   Switzerland;
Experimental: CRH administration
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2021   Phase 4   NCT04902235   Spain;
Experimental: GLP1-RA (exenatide) administration
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2021   Phase 4   NCT04897802   Spain;
IUPAC
   Sanofi-Synthelabo Research
      2004   -   EUCTR2004-002349-11-ES   Spain;
Oxytocin nasal spray
   Elizabeth Austen Lawson
      2022   Phase 1   NCT04789148   United States;
SAMSCA*10CPR
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2012   -   EUCTR2012-004071-39-IT   Italy;
SR121463B
   Sanofi
      2005   Phase 3   NCT00264914   Australia;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Russian Federation;Switzerland;United States;
      2004   Phase 3   NCT00264927   Belgium;Brazil;Canada;Croatia;Germany;Hong Kong;Hungary;Netherlands;Portugal;Spain;United States;
   Sanofi-Synthelabo Research
      2005   Phase 3   EUCTR2004-005239-25-ES   Germany;Hungary;Spain;
      2005   Phase 3   EUCTR2004-003985-14-BE   Belgium;Denmark;Hungary;Sweden;
      2005   -   EUCTR2004-005239-25-HU   Germany;Hungary;Spain;
      2005   -   EUCTR2004-005239-25-DE   Germany;Hungary;Spain;
      2005   -   EUCTR2004-003985-14-HU   Denmark;Hungary;Sweden;
      2004   -   EUCTR2004-002349-11-ES   Spain;
   sanofi-aventis recherche & développement
      2005   -   EUCTR2004-003985-14-SE   Denmark;Hungary;Sweden;
      2005   -   EUCTR2004-003985-14-DK   Denmark;Hungary;Sweden;
   sanofi-aventis recherche et développement
      2008   Phase 3   EUCTR2007-007941-10-FR   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-HU   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-DE   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-BE   Belgium;France;Germany;Hungary;
Samsca
   Department of Medical Research
      2014   Phase 2   EUCTR2013-003800-38-DK   Denmark;
      2012   Phase 2   EUCTR2012-001169-33-DK   Denmark;
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark;
Satavaptan
   sanofi-aventis recherche et développement
      2008   Phase 3   EUCTR2007-007941-10-FR   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-HU   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-DE   Belgium;France;Germany;Hungary;
      2008   -   EUCTR2007-007941-10-BE   Belgium;France;Germany;Hungary;
Satavaptan (SR121463)
   Sanofi
      2008   Phase 3   NCT00728091   United States;
Satavaptan (SR121463B)
   Sanofi
      2001   Phase 2   NCT00032734   Belgium;Canada;France;Germany;Hungary;United States;
Tolvaptan
   Otsuka Frankfurt Research Institute GmbH
      2010   -   NCT01228682   Denmark;Germany;Italy;Norway;Spain;Sweden;United Kingdom;
   Otsuka Pharmaceutical Co., LTD.
      2017   Phase 3   JPRN-JapicCTI-173512   Japan;
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2013   Phase 1/Phase 2   NCT02009878   Czech Republic;Denmark;Germany;Hungary;Spain;Sweden;United Kingdom;
      2010   Phase 3   NCT01227512   United States;
      2003   Phase 3   NCT00201994   Germany;
      2003   Phase 3   NCT00072683   United States;
   Polderman, Kees, H., MD, PhD
      2015   -   NCT02545114   United States;
Tolvaptan (SAMSCA)
   Otsuka Pharmaceutical Co., Ltd.
      2021   -   NCT04790175   Japan;
Tolvaptan Oral Tablet
   Otsuka Pharmaceutical Co., Ltd.
      2017   Phase 3   NCT03048747   Japan;
Tolvaptan in euvolemic hyponatremia
   NYU Langone Health
      2011   -   NCT01425125   United States;
Urea
   Helbert Rondon Berrios, MD, MS
      2022   Phase 2   NCT04588207   United States;
   University Hospital, Grenoble
      2020   -   NCT04552873   France;